phase I clinical study
Researchers hope their study will show that tests for gene variants and DNA methylation can predict which lower-risk patients may be cured without a stem cell transplant.
FDA Approves Takeda's Exkivity With Thermo Fisher CDx for EGFR Exon20 Insertion-Positive NSCLC
This is the first time the FDA has approved a drug specifically for NSCLC patients who harbor rare EGFR Exon20 insertion mutations.
FDA Approves GlaxoSmithKline's Jemperli, Roche’s Ventana CDx for dMMR Solid Cancers
The approval expands the label for GSK's anti-PD-1 agent dostarlimab, which the FDA initially approved in April for patients with dMMR endometrial cancers.
Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib
The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib.
MapKure, Personalis Partner to Screen Patients for BRAF Inhibitor Trial
Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study.